While anti-VEGF therapy is the standard for DME and nAMD, managing nonresponders with persistent fluid remains a clinical ...
Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today ...
The recent approval of Regeneron’s Otarmeni underscores the maturation of gene therapies across a range of diseases. Here, ...
In patients with proliferative diabetic retinopathy, treatment with anti–vascular endothelial growth factor (anti-VEGF) may offer a safer alternative to panretinal photocoagulation (PRP), leading to ...
MedPage Today on MSN
VEGF inhibitor implant preserves visual acuity, retinal anatomy in wet AMD
Good baseline visual acuity retained in three-fourths of patients at 36 weeks with OTX-TKI ...
Please provide your email address to receive an email when new articles are posted on . The programs are designed to provide anti-VEGF treatment for patients who are uninsured or underinsured.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results